Immunohistochemical analysis indicates that SRPK1 is expressed at low levels or not expressed in normal brain tissue, while it is highly expressed in grade IV gliomas and is expressed to a lesser extent in grade III gliomas (Figure 1C), with expression levels positively correlated with glioma grading (Figure 1D). This evidence concerns the gene SRPK1 and central nervous system cancer.